Ohr Pharmaceuticals (NASDAQ: OHRP) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.
Institutional and Insider Ownership
8.4% of Ohr Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.5% of Compugen shares are owned by institutional investors. 17.4% of Ohr Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Ohr Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Compugen has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Ohr Pharmaceuticals and Compugen, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ohr Pharmaceuticals presently has a consensus target price of $8.50, indicating a potential upside of 470.47%. Compugen has a consensus target price of $14.00, indicating a potential upside of 471.43%. Given Compugen’s higher possible upside, analysts plainly believe Compugen is more favorable than Ohr Pharmaceuticals.
This table compares Ohr Pharmaceuticals and Compugen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Ohr Pharmaceuticals and Compugen’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ohr Pharmaceuticals||N/A||N/A||-$25.76 million||($0.70)||-2.13|
Ohr Pharmaceuticals has higher earnings, but lower revenue than Compugen. Compugen is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.